trial

A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

NCTId NCT06980207
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Not Yet Recruiting
Enrollment 40 (estimated)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2025-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Not Yet Recruiting
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
Quadruple
Start
2025-05
Primary completion
2025-10
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
LY03017

Sponsors

Luye Pharma Group Ltd.Lead Sponsor

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE1
Primary Completion Date
2025-10
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
LY03017
drug
lead_sponsor
Luye Pharma Group Ltd.
company
indication
Hallucinations
indication
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
indication
Negative Symptoms of Schizophrenia
indication